143 related articles for article (PubMed ID: 11851646)
1. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
Saima S; Furuie K; Yoshimoto H; Fukuda J; Hayashi T; Echizen H
Br J Clin Pharmacol; 2002 Feb; 53(2):203-6. PubMed ID: 11851646
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.
Tokuma Y; Fujiwara T; Noguchi H
Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):229-37. PubMed ID: 3659571
[TBL] [Abstract][Full Text] [Related]
3. Interaction of some drugs on the pharmacokinetics or pharmacodynamics of MPC-1304, a dihydropyridine Ca2+ antagonist.
Nakano M; Miyoshi K; Umeno Y; Yoshida K; Nishizaki J; Miyake H
Arch Int Pharmacodyn Ther; 1996; 331(2):109-23. PubMed ID: 8937623
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of nilvadipine in healthy volunteers.
Terakawa M; Tokuma Y; Shishido A; Noguchi H
J Clin Pharmacol; 1987 Feb; 27(2):111-7. PubMed ID: 3680562
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.
van Harten J; van Brummelen P; Lodewijks MT; Danhof M; Breimer DD
Clin Pharmacol Ther; 1988 Mar; 43(3):332-41. PubMed ID: 3345623
[TBL] [Abstract][Full Text] [Related]
6. Nilvadipine: profile of a new calcium antagonist. An overview.
Rosenthal J
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
[TBL] [Abstract][Full Text] [Related]
7. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine.
Ndanusa BU; Mustapha A; Abdu-Aguye I
J Pharm Biomed Anal; 1997 Jun; 15(9-10):1571-5. PubMed ID: 9226591
[TBL] [Abstract][Full Text] [Related]
8. Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine.
Cheung WK; Sia LL; Woodward DL; Graveline JF; Desjardins RE; Yacobi A; Silber BM
J Clin Pharmacol; 1988 Nov; 28(11):1001-7. PubMed ID: 3243913
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease.
Takata Y; Yoshizumi T; Ito Y; Kikuchi M; Ueno M; Tsukashima A; Kobayashi K; Fujishima M
Eur J Clin Pharmacol; 1992; 42(5):475-9. PubMed ID: 1606993
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.
Yeo KP; Lowe SL; Lim MT; Voelker JR; Burkey JL; Wise SD
Br J Clin Pharmacol; 2006 Feb; 61(2):200-10. PubMed ID: 16433874
[TBL] [Abstract][Full Text] [Related]
12. Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.
van Harten J; Burggraaf J; van Brummelen P; Breimer DD
Clin Pharmacokinet; 1989 Jan; 16(1):55-64. PubMed ID: 2706880
[TBL] [Abstract][Full Text] [Related]
13. Effect of lomerizine, a new Ca(2+)channel blocker, on the microcirculation in the optic nerve head in conscious rabbits: a study using a laser speckle technique.
Shimazawa M; Sugiyama T; Azuma I; Araie M; Iwakura Y; Watari M; Sakai T; Hara H
Exp Eye Res; 1999 Aug; 69(2):185-93. PubMed ID: 10433855
[TBL] [Abstract][Full Text] [Related]
14. A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction.
Mårde Arrhén Y; Nylén H; Lövgren-Sandblom A; Kanebratt KP; Wide K; Diczfalusy U
Br J Clin Pharmacol; 2013 Jun; 75(6):1536-40. PubMed ID: 23116409
[TBL] [Abstract][Full Text] [Related]
15. Effects of nilvadipine (a dihydropyridine-type calcium entry blocker) on cerebral blood flow in acute experimental brain ischemia in rats.
Tanaka R; Miyasaka Y; Maruyama S; Nagai S; Fujii K
Neurol Res; 1996 Aug; 18(4):325-8. PubMed ID: 8875450
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers.
Terakawa M; Tokuma Y; Kuwahara N; Shishido A; Noguchi H
J Clin Pharmacol; 1988 Apr; 28(4):350-5. PubMed ID: 3392233
[TBL] [Abstract][Full Text] [Related]
17. Effects of nilvadipine on regional cerebral blood flow and skin blood flow in anesthetized cats.
Takakura S; Satoh Y; Satoh H; Mori J; Kohsaka M
Arch Int Pharmacodyn Ther; 1992; 319():38-48. PubMed ID: 1285672
[TBL] [Abstract][Full Text] [Related]
18. Nilvadipine in hypertension with renal dysfunction.
Berger HH; Albert FW
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S73-9. PubMed ID: 1283194
[TBL] [Abstract][Full Text] [Related]
19. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.
van Harten J; van Brummelen P; Wilson JH; Lodewijks MT; Breimer DD
Eur J Clin Pharmacol; 1988; 34(4):387-94. PubMed ID: 3402524
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension.
Weir MR; Vlachkis ND; DeQuattro V; Douglas J; Svetkey LP; Singh S; Wiedl SC; Chen CF; Woodward DL; Saunders E
J Clin Pharmacol; 1990 May; 30(5):425-37. PubMed ID: 2189903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
